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Recent evidence suggests a role of transient receptor potential melastatin 2 (TRPM2) in immune and
inﬂammatory responses. We previously reported that TRPM2 deﬁciency attenuated inﬂammatory and
neuropathic pain in some pain mouse models, including formalin- or carrageenan-induced inﬂammatory
pain, and peripheral nerve injury-induced neuropathic pain models, while it had no effect on the basal
mechanical and thermal nociceptive sensitivities. In this study, we further explored the involvement of
TRPM2 in various pain models using TRPM2-knockout mice. There were no differences in the chemo-
nociceptive behaviors evoked by intraplantar injection of capsaicin or hydrogen peroxide between
wildtype and TRPM2-knockout mice, while acetic acid-induced writhing behavior was signiﬁcantly
attenuated in TRPM2-knockout mice. In the postoperative incisional pain model, no difference in me-
chanical allodynia was observed between the two genotypes. By contrast, mechanical allodynia in the
monosodium iodoacetate-induced osteoarthritis pain model and the experimental autoimmune
encephalomyelitis model were signiﬁcantly attenuated in TRPM2-knockout mice. Furthermore, me-
chanical allodynia in paclitaxel-induced peripheral neuropathy and streptozotocin-induced painful
diabetic neuropathy models were signiﬁcantly attenuated in TRPM2-knockout mice. Taken together,
these results suggest that TRPM2 plays roles in a wide range of pathological pain models based on pe-
ripheral and central neuroinﬂammation, rather than physiological nociceptive pain.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Pathological pain is mediated through pathologically enhanced
pain pathways induced by a variety of causes, such as inﬂammation,
arthritis, surgical incision, peripheral/central nerve injury, demye-
lination, diabetes, and some classes of chemotherapeutic agents.
Several lines of evidence suggest that neuroinﬂammationmediated
by the interaction between immune cells and nociceptive neurons
plays a key role in pathological pain (1,2). Circulating immune cellsrmacology and Therapeutics,
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d/4.0/).inﬁltrate in response to peripheral tissue damage, inﬂammation, or
nerve injury. Pronociceptive inﬂammatory mediators such as
proinﬂammatory cytokines, chemokines, and reactive oxygen
species (ROS) released from the inﬁltrated immune cells can in-
crease the sensitivity of nociceptive primary sensory neurons, i.e.
peripheral sensitization. In addition, the prolonged or intense hy-
perexcitability of peripheral nociceptive neurons can trigger hy-
perexcitability of the nociceptive dorsal horn neurons in the spinal
cord, i.e. central sensitization. Accumulating evidence suggests that
the activation of spinal glial cells, such as microglia and astrocytes,
contribute to the generation of central sensitization thorough the
production of pronociceptive inﬂammatory mediators (3).
Transient receptor potential melastatin 2 (TRPM2) channel is
expressed abundantly in immune cells, including monocytes/mac-
rophages, neutrophils, T-lymphocytes, andmicroglia (4e6), and actsnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
K. So et al. / Journal of Pharmacological Sciences 127 (2015) 237e243238as a sensor for ROS (7e9). A growingbodyof evidence suggests a role
for TRPM2 in immune and inﬂammatory responses (6,10e14).
Recently, we reported the involvement of TRPM2 expressed on
macrophages andmicroglia in pathological pain (15,16).We showed
that painful behaviors in inﬂammatory pain models (such as the
second phase of the formalin test, and the carrageenan-induced
inﬂammatory pain model) and neuropathic pain models induced
by peripheral nerve injury (such as partial sciatic nerve ligation and
spinal nerve transaction) are attenuated in TRPM2-knockout (KO)
mice. By contrast, the basal thermal (Hargreaves test and hot plate
test), mechanical (von Frey ﬁlament test), and chemical (ﬁrst phase
of the formalin test) nociceptive sensitivities were unaffected in
TRPM2-KO mice. These ﬁndings suggest that TRPM2 could be a
promising drug target for the treatment of pathological pain.
However, pathological pain can arise from not only tissue inﬂam-
mation and peripheral nerve injury, but also from other causes.
Recent studies established avariety of rodentmodels of pathological
pain that showmore clinically relevant pain states (17). In this study,
to explore the types of pain mediated via TRPM2, we further
examined the effects of TRPM2 deﬁciency in various mouse pain
models, including capsaicin or hydrogen peroxide (H2O2)-evoked
chemical nociceptive pain, acetic acid-induced writhing behaviors,
osteoarthritis pain, postoperative pain, chronic pain in multiple
sclerosis models, painful diabetic neuropathy, and chemotherapy-
induced peripheral neuropathy in mice.
2. Methods
2.1. Animals
This study was carried out in strict accordance with the recom-
mendations of the Guiding Principles for the Care and Use of Ani-
mals of The Japanese Pharmacological Society. The protocol was
approved by the Kyoto University Animal Research Committee
(Permit Number: 2012e24 and 2013e24). All efforts were made to
minimize the number of animals used, and limit experimentation to
onlywhatwas necessary to produce, as previously reported.Male or
female mice aged 7e12 weeks were used in this study. TRPM2-KO
mice were generated as previously reported (12). The TRPM2-KO
mouse line was backcrossed with C57BL/6J mice for seven to ten
generations to eliminate any background effects on the phenotypes.
The mice were kept at a constant ambient temperature of 24 ± 1 C
under a 12 h light/dark cycle with free access to food and water.
2.2. von Frey ﬁlament test
Mechanical sensitivity was assessed by the up-down method
using calibrated von Frey ﬁlaments as previously described, with
slight modiﬁcations (18,19). Mice were acclimatized on a metal
mesh ﬂoor in small cylinders for 2 h. The mechanical sensitivity
was evaluated using a set of seven calibrated von Frey ﬁlaments
(0.008, 0.02, 0.04, 0.07, 0.16, 0.4, and 1.0 g; Stoelting) that were
applied to the plantar surface of the hind paw until the ﬁlament
bent slightly for a few seconds. The 0.16 g ﬁlament was always the
ﬁrst stimulus. When there was a positive response, such as ﬂicking
or lifting, the next lower ﬁlament was applied, and when there was
no response, the next higher ﬁlament was used. The 50% paw
withdrawal threshold value was calculated from ﬁve consecutive
responses (18,20).
2.3. Chemical nociceptive behavior to the intraplantar injection of
capsaicin or H2O2
Chemical nociceptive behavior to the intraplantar injection of
capsaicin or H2O2 was assessed as previously described, with slightmodiﬁcations (21,22). Capsaicin (80 mg/ml; Nacalai Tesque, Kyoto,
Japan) and H2O2 (0.3%; Wako Pure Chemical Industries, Ltd., Osaka,
Japan) were prepared in corn oil and sterile saline (0.9%), respec-
tively. Male WT and TRPM2-KO mice were individually acclima-
tized to an acrylic observation chamber 25 cm in diameter and
30 cm in height for approximately 1 h before the injection. 20 mL of
capsaicin (1.6 mg/paw) or 0.3% H2O2 was injected in the plantar
surface of the right hind paw, using a Hamilton syringe with a 30-
gauge needle. The mouse was then put in the chamber and the
period of observation started. Vehicle control animals, receiving an
intraplantar injection of corn oil or saline, were also observed un-
der identical conditions. Because both capsaicin- and H2O2-evoked
nociceptive behaviors appear immediately, and decay within 5 min
(21,22), the total time spent licking and biting the injected pawwas
recorded for 5 min after the injection.
2.4. Acetic acid-induced writhing test
WT and TRPM2-KO mice were acclimatized in individual
observation cages for 1 h. The mice were intraperitoneally injected
with a 0.9% acetic acid solution (10 ml/kg), and then returned to
their cages. The number of typical writhing behaviors, character-
ized by the contraction of the abdominal musculature followed by
extension of the hind limbs, was counted for 30 min.
2.5. Postoperative incisional pain model
For the postoperative pain model, the surgery was performed as
previously described (23), and adapted to mice (24). Brieﬂy, male
WT and TRPM2-KO mice were anesthetized with isoﬂurane. After
sterile preparation of the right hind paw, a 5 mm longitudinal
incisionwasmade through the skin and fascia of the plantar surface
using a No. 11 scalpel blade. The incision started 2 mm from the
proximal edge of the heel and extended toward the toes. The
plantaris muscle was elevated with forceps, leaving the muscle
origin and insertion intact. The skinwas closed with one single 7e0
surgical silk suture. Mechanical sensitivity was assessed before and
6 h, 1, 3, 5, 7, 10 and 14 days after the incision, as described above.
2.6. Monosodium iodoacetate (MIA)-induced osteoarthritis pain
model
Osteoarthritis was induced by a single intra-articular injection
of MIA (SigmaeAldrich, St. Louis, MO) into the knee, following a
previously described protocol, with slight modiﬁcations (25).
Brieﬂy, male WT and TRPM2-KO mice were anesthetized with
isoﬂurane, and the knee joints were shaved and ﬂexed at a 90
angle. 10 ml of 10 mg/ml MIA in sterile saline (0.9%) was injected
through the infra-patellar ligament into the joint space of the right
(ipsilateral) knee using a 30-gauge needle. Mice in which the 50%
paw withdrawal threshold was decreased under 0.4 g at 21 days
after the MIA administrationwere used. Mechanical sensitivity was
assessed before and 1, 3, 7, 10, 14 and 21 days after the intra-
articular injection, as described above.
2.7. Induction of the experimental autoimmune encephalomyelitis
(EAE) model and assessment of the clinical severity of the EAE
For the induction of the EAE model, the procedures were per-
formed as previously described (26). Female WT and TRPM2-KO
mice were subcutaneously (s.c.) immunized in both ﬂanks with
the MOG35e55 peptide (20 or 100 mg per animal; Operon Bio-
technologies, Inc., Tokyo, Japan) in 200 mL of an emulsion consisting
of a 1:1 (volume/volume) mixture of physiological saline and
complete Freund's adjuvant (CFA), the latter of which contained
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Co., Franklin Lakes, NJ). An i.p. injection of 200 ng pertussis toxin
(List Biological Laboratories, Inc., Campbell, CA) was administered
at the time of the induction and again 48 h later. Control mice were
treated with CFA and pertussis toxin alone. For the assessment of
the clinical severity of the EAE, the clinical scores of EAE were
graded according to the following scale: Score 0, normal mouse;
Score 1, tail paralysis; Score 2, mild hind limb weakness; Score 3,
moderate to severe hind limb paralysis and/or mild forelimb
weakness; Score 4, complete hind limb paralysis and/or moderate
to severe forelimb weakness; Score 5, quadriplegia or moribund
state; Score 6, death. Mice were monitored daily for clinical signs of
EAE. Mechanical sensitivity was assessed before and 1, 3, 5, 7, 9, 11,
13, 15, 17, 19, 22, 25 and 27 days after the treatment, as described
above.
2.8. Paclitaxel-induced neuropathic pain model
Paclitaxel (SigmaeAldrich) was dissolved in cremophor:-
ethanol:saline (5:5:90, v/v/v). Male WT and TRPM2-KO mice were
injected with paclitaxel (4 mg/kg; i.p.) once daily on day 0, 3, 5, and
7, as previously described, with slight modiﬁcations (27). Mice
injected with the ethanol:cremophor:saline vehicle were used as
control mice. Mechanical sensitivity was assessed before and 4, 7,
14 and 21 days after the injection, as described above.
2.9. Streptozotocin (STZ)-induced diabetic neuropathic pain model
Diabetes was induced by tail vein injection of STZ (Sigma-
eAldrich), dissolved in sterile saline (0.9%), at a dose of 75 mg/kg
intomaleWTand TRPM2-KOmice. Bloodwas sampled from the tail
vein, and the glucose level was measured by using the One-Touch
Ultra Blood Glucose Monitoring System (Johnson & Johnson, NewFig. 1. Effect of TRPM2 deﬁciency on capsaicin or H2O2-evoked chemical nociceptive
behaviors. WT and TRPM2-KO mice were injected intraplantarly (i.pl.) with (A) vehicle
or capsaicin (1.6 mg/paw), (B) saline or 0.3% H2O2 solution. The duration of licking and
biting behaviors to the injected paw was measured for 5 min following the injection
n ¼ 4e6.Brunswick, NJ). Micewere deemed diabetic when the blood glucose
concentration exceeded 200 mg/dL. Mechanical sensitivity was
assessed before and 7 and 14 days after the injection, as described
above.
2.10. Statistical analysis
Datawere expressed asmeans ± S.E.M. Statistical analyses of the
50% paw withdrawal thresholds were performed using the Man-
neWhitney U-test at the individual time points. The EAE scores and
blood glucose levels were analyzed by a two-way analysis of vari-
ance (ANOVA), followed by the Bonferroni's post hoc comparison
test. To analyze other behavioral responses, we used the Student's
t-test for comparisons between two mean values. Differences with
P < 0.05 were considered signiﬁcant.
3. Results
3.1. Nociceptive responses to chemical stimuli
Nociceptive responses to acute chemical stimuli were compared
between wildtype (WT) and TRPM2-KO mice. Following an intra-
plantar (i.pl.) injection of capsaicin, licking and biting were
observed in both WT and TRPM2-KO mice, but no nociceptive be-
haviors were observed after an i.pl. injection of the vehicle. No
signiﬁcant difference was observed between WT and TRPM2-KO
mice with respect to the duration of capsaicin-evoked nociceptive
behaviors (Fig. 1A). Similarly, there was no signiﬁcant difference in
the duration of licking and biting evoked by an i.pl. injection of
H2O2 between WT and TRPM2-KO mice (Fig. 1B).
3.2. Acetic acid-induced writhing test
An intraperitoneal (i.p.) injection of acetic acid into WT mice
induced writhing behavior, which peaked 5e10 min after the in-
jection. TRPM2-KO mice exhibited signiﬁcantly fewer writhing
behaviors than the WT mice (Fig. 2).
3.3. Postoperative incisional pain model
A surgical incision in the plantar aspect of the hind paw
decreased the 50% paw withdrawal thresholds of the ipsilateral
hind paw in both WT and TRPM2-KO mice. The withdrawal
thresholds peaked at 6 h, and lasted for at least 14 days after the
incision. There was no signiﬁcant difference between WT andFig. 2. Effect of TRPM2 deﬁciency on acetic acid-induced writhing behaviors. WT
(n ¼ 6) and TRPM2-KO mice (n ¼ 8) were injected intraperitoneally (i.p.) with 0.9%
acetic acid solution (10 ml/kg). The number of typical writhing behaviors was counted
every 5-min over 30 min (A). *P < 0.05, compared with WT mice. (B) Total number of
writhing behaviors for 30 min **P < 0.01.
Fig. 3. Effect of TRPM2 deﬁciency on mechanical allodynia in the postoperative inci-
sional pain model. The plantar surface of WT and TRPM2-KO mice were incised, as
described in the Materials and Methods. The 50% paw withdrawal thresholds in the
ipsilateral and contralateral paws were determined 6 h, 1, 2, 3, 5, 7, 10 and 14 days after
the incision n ¼ 7.
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thresholds of the contralateral hind paw were unaffected by the
incision (Fig. 3).
3.4. MIA-induced osteoarthritis pain model
An intra-articular injection of MIA, but not of saline, into the
knee decreased the 50% pawwithdrawal threshold of the ipsilateral
hind paw. The number of MIA-induced osteoarthritis-developed
mice, in which the 50% paw withdrawal threshold was lower than
0.4 g, was six out of nine forWTmice and ﬁve out of ten for TRPM2-
KO mice, respectively. There was no signiﬁcant difference in the
incidence rate of osteoarthritis between WT and TRPM2-KO mice.
However, the decrease in 50% pawwithdrawal threshold in TRPM2-
KO mice was signiﬁcantly attenuated compared with that in WT
mice (Fig. 4).
3.5. Clinical signs and mechanical allodynia in EAE model
When WT and TRPM2-KO mice were treated with CFA and
pertussis toxin alone, in the absence of myelin oligodendrocyte
glycoprotein (MOG)35e55 peptide, the clinical signs of EAE were notFig. 4. Effect of TRPM2 deﬁciency on mechanical allodynia in the MIA-induced oste-
oarthritis pain model. Vehicle or MIAwas injected intra-articularly into the knee of WT
and TRPM2-KO mice. The 50% paw withdrawal thresholds in the ipsilateral paws were
determined. n ¼ 5e6. *P < 0.05, **P < 0.01 vs ipsilateral-WT mice.observed. When WT mice were immunized with 100 mg MOG35e55
peptide, the mice began to develop clinical signs between 11 and 12
days post-immunization. The clinical score of the EAE in TRPM2-KO
mice was signiﬁcantly attenuated compared with that in WT mice
(Fig. 5A). However, because EAE induced by 100 mg MOG35e55
peptide showed severe clinical signs including paralysis, it was
impossible to precisely measure the 50% paw withdrawal
threshold. Therefore, mice were immunized with a lower dose of
MOG35e55 peptide to induce weak EAE severity. When WT mice
were immunized with 20 mg MOG35e55 peptide, weak clinical signs
were observed between 15 and 28 days, which did not include
paralysis. The clinical score of the EAE in TRPM2-KO mice was
attenuated compared with that in WT mice (Fig. 5B). The 50% paw
withdrawal threshold began to decrease at day 1, and reached a
plateau by 3 days post-immunization. In TRPM2-KO mice, the
decrease in 50% paw withdrawal threshold was signiﬁcantlyFig. 5. Effect of TRPM2 deﬁciency on clinical signs and mechanical allodynia in the EAE
model. Female WT and TRPM2-KO mice were immunized with vehicle, or with 100 mg
(A; MOG100) or 20 mg (B, C; MOG20) MOG35e55 peptide. (A, B) Clinical signs of EAE
were scored daily over 28 days after post-immunization. (C) The 50% paw withdrawal
threshold was determined. n ¼ 4e10 *P < 0.05, **P < 0.01, ***P < 0.001 vs WT mice.
Fig. 7. Effect of TRPM2 deﬁciency on blood glucose level and mechanical allodynia in
the STZ-induced peripheral neuropathic pain model. WT and TRPM2-KO mice were
injected intravenously (i.v.) with vehicle or STZ (75 mg/kg). (A) Blood glucose levels
were measured 14 days after STZ injection. (B) The 50% paw withdrawal thresholds
were determined. n ¼ 5. **P < 0.01 vs STZ-WT mice.
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treatment without MOG35e55 peptide did not change the 50% paw
withdrawal threshold (Fig. 5C).
3.6. Paclitaxel-induced neuropathic pain model
When WT mice were repeatedly treated i.p. with paclitaxel
(4 mg/kg; 4 times), the 50% paw withdrawal threshold was grad-
ually decreased 4, 7, 14 and 21 days after the ﬁrst injection, and
remained unchanged even after repeated injection of vehicle using
the same schedule. In TRPM2-KO mice, the decrease in 50% paw
withdrawal threshold was signiﬁcantly attenuated compared with
that in WT mice (Fig. 6).
3.7. STZ-induced diabetic neuropathic pain model
Fourteen days after the STZ-treatment, the blood glucose level
signiﬁcantly increased compared with that of the vehicle-treated
control mice. There was no signiﬁcant difference in the blood
glucose levels between WT and TRPM2-KO mice after vehicle- or
STZ-treatment, although TRPM2-KO mice showed slightly higher
blood glucose levels than WT mice (Fig. 7A). In WT mice treated
with STZ, the 50% pawwithdrawal threshold decreased over 7 days,
and recovered 14 days after the treatment, but remained un-
changed in the vehicle-treated mice. In TRPM2-KO mice, the
decrease in 50% paw withdrawal threshold 7 days after the STZ-
treatment was signiﬁcantly attenuated compared with that in WT
mice (Fig. 7B).
4. Discussion
In the present study, we showed that TRPM2 deﬁciency atten-
uated painful behavior in various pathological pain models
including acetic acid-induced writhing behavior, MIA-induced
osteoarthritis pain, chronic pain in the EAE model, paclitaxel-
induced peripheral neuropathy, and STZ-induced painful diabetic
neuropathy. By contrast, TRPM2 deﬁciency had no effect on
capsaicin- or H2O2-evoked chemical nociceptive pain or on me-
chanical allodynia in the postoperative incisional painmodel. These
results suggest that TRPM2 plays key roles in a wide range of
pathological inﬂammatory and neuropathic pain, but not in noci-
ceptive pain.
Nociceptive pain is deﬁned as “pain arising from activation of
nociceptors” (28). Nociceptive pain is generated when thermal,Fig. 6. Effect of TRPM2 deﬁciency on mechanical allodynia in the paclitaxel-induced
peripheral neuropathic pain model. WT and TRPM2-KO mice were injected intraper-
itoneally with vehicle or paclitaxel (4 mg/kg; 4 times). The 50% paw withdrawal
thresholds were determined. n ¼ 4e5. *P < 0.05, **P < 0.01 vs WT mice.mechanical, or chemical noxious stimuli activate nociceptors
located on the peripheral terminals of primary sensory neurons.
Tissue injury, inﬂammation or infection produces various prono-
ciceptive mediators, which activate nociceptors to elicit nociceptive
pain (29). Capsaicin and H2O2-evoked nociceptive behaviors
represent the acute chemonociceptive pain in responses to stimu-
lation of TRPV1 and TRPA1 (22,30). Although recent studies re-
ported that functional TRPM2 is also expressed in the dorsal root
ganglion neurons (31), the present results, taken together with our
previous ﬁndings (15), suggest that TRPM2 expressed on sensory
neurons plays no role, at least, in exogenous ROS-evoked acute
nociceptive pain. By contrast, TRPM2 deﬁciency attenuated the
acetic acid-induced writhing behavior, which is recognized as an
acute inﬂammatory pain model. The acetic acid-induced writhing
response is mediated by the rapid inﬁltration of neutrophils into
the peritoneal cavity. Neutrophil depletion by the treatment with
anti-Ly6G antibody attenuates the acetic acid-induced writhing
response (32). We reported that TRPM2 deﬁciency reduces the
inﬁltration of neutrophils into the inﬂamed sites, resulting inhibi-
tion of mechanical allodynia and thermal hyperalgesia in
carrageenan-induced inﬂammatory pain model (15). Taken
together, these ﬁndings suggest that TRPM2 is involved in acetic-
acid induced inﬂammatory pain, but not in acute chemo-
nociceptive pain signaling.
Postoperative incisional pain is classiﬁed as acute spontaneous
pain. Sensitized and spontaneously activated peripheral sensory
neurons mainly contribute to the initiation of postoperative inci-
sional pain (33), while peripheral and central inﬂammatory
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temic or intrathecal administration of non-steroidal anti-inﬂam-
matory drugs shows a weak analgesic effect on postoperative
incisional pain (34). Furthermore, microglia and astrocytes in the
spinal cord are rapidly and transiently activated after paw incision,
which is accompanied with mechanical allodynia (35,36). Although
we cannot fully explain why postoperative incisional pain was not
affected in TRPM2-KO mice, it may include a strong aspect of
nociceptive pain, rather than inﬂammatory pain. Alternatively,
postoperative incisional pain is caused by an incision of skin and
deep tissue including fascia and muscle layer, resulting in the
enhanced activity of muscle-innervating primary sensory neurons
and the dorsal horn neurons received from muscle (37). Muscle
pain induced by deep tissue incision may be less affected by
TRPM2-mediated inﬂammation. The present results indicate that
the role of TRPM2 is minimal in postoperative incisional pain,
although further investigations will be needed to elucidate this
discrepancy.
Osteoarthritis, the most common joint disease, is characterized
by the degeneration of articular cartilage, and the major clinical
symptoms are chronic pain and disability. Osteoarthritis is not
considered as a classical inﬂammatory arthropathy, because of no
manifestations of inﬂammation and absence of neutrophils in the
synovial ﬂuid. However, dysfunction of the chondrocytes is caused
by synovial inﬂammation, including the inﬁltration of activated B-
cells and T-lymphocytes and the production of proinﬂammatory
mediators (38). Thus, osteoarthritis pain is induced by not only
local tissue damage, but also these complex causes, which lead to
peripheral sensitization (39). Furthermore, the activation of
microglia has been observed, and a microglial inhibitor, minocy-
cline, attenuated mechanical allodynia in MIA-induced osteoar-
thritis pain model (40). Taken together, the present results suggest
that TRPM2 may be involved in immune and inﬂammatory pro-
cesses in the knee joint and/or activation of spinal microglia acti-
vation associated with osteoarthritis in MIA-induced osteoarthritis
pain model.
EAE is an animal model of multiple sclerosis, an autoimmune
disease of the central nervous system (CNS). The pathological
characteristics of multiple sclerosis include the inﬁltration of T-cells
into the CNS, demyelination, and axonal degeneration in the CNS
(41). Consistent with the present results, Melzer et al. reported that
TRPM2-KO mice exhibited attenuated EAE scores, and reduced in-
ﬂammatory and demyelinating spinal cord lesions. Furthermore,
they showed that TRPM2 plays a critical role in T-cell proliferation
and the secretion of proinﬂammatory cytokines, such as IL-2,
interferon-g and IL-17, following polyclonal T-cell receptor stimu-
lation (42)．These ﬁndings suggest that the modulation of T-cell
effectors via TRPM2 contribute to exhibit EAE symptoms. On the
other hand, mice immunized with MOG showmechanical and cold
allodynia, which are developed before the emergence of any
neurological deﬁcit signs, and is independent of the symptom
severity (43). It is suggested that spinal inﬁltration of T-cells and
activation of astrocyte and microglia/macrophages in the spinal
cord may play a critical role in allodynia in EAE model (43e45). We
recently reported that TRPM2 is involved in the spinal inﬁltration of
peripheral immune cells in peripheral nerve injury-induced
neuropathic pain model (16). Therefore, it is possible that the
attenuation of mechanical allodynia in TRPM2-KOmice may be due
to not only the inhibition of resident microglial activation, but also
the inhibition of spinal inﬁltration of peripheral immune cells.
Paclitaxel exerts its anti-cancer effects by increasing the stability
of tubulin polymers to inhibit cellular replication, while it
frequently induces severe peripheral neuropathy. Although the
mechanisms still remain unclear, paclitaxel-induced peripheral
neuropathy is associated with the swollen and vacuolatedmitochondria in the peripheral sensory neurons (46). The mito-
chondrial dysfunction produces oxidative stress, which leads to
neurotoxicity and axonal degeneration in peripheral sensory neu-
rons. Accumulating evidence suggest that TRPM2 plays a critical
role in oxidative stress-induced cell injury (9). Thus, it is suggested
that TRPM2 contributes to paclitaxel-induced peripheral neurop-
athy via oxidative stress-induced injury of peripheral sensory
neurons. In addition, the inﬂammatory responses of peripheral
immune cells and spinal glial cells are also involved in
chemotherapy-induced peripheral neuropathy (47,48), suggesting
that peripheral and spinal neuroinﬂammation via TRPM2 contrib-
utes to the induction of peripheral and central sensitization asso-
ciated with paclitaxel-induced peripheral neuropathy.
TRPM2 is involved in oxidative stress in the pancreatic b-cells
(49), and the regulation of insulin secretion and glucose homeo-
stasis in mice (50,51). In isolated b-cells prepared from TRPM2-KO
mice, glucose-induced insulin secretion was blunted in a high-
glucose environment (50). Uchida et al. reported that TRPM2-KO
mice showed higher blood glucose levels than WT mice in intra-
peritoneal glucose tolerance tests (50), while Zhang et al. showed
improvement of glucose tolerance in TRPM2-KO mice (51). The
present results showed that basal fasting blood glucose levels did
not differ between WT and TRPM2-KO mice. Painful neuropathy is
one of the most common complications of diabetes. Hyperglyce-
mia, dyslipidemia, and insulin resistance are responsible for dia-
betic neuropathy. Several lines of evidence suggest that
inﬂammation and mitochondrial dysfunction resulting from the
diabetic state contribute to oxidative stress and nerve injury in
diabetic neuropathy (52,53). Thus, TRPM2 may contribute to STZ-
induced painful diabetic neuropathy via the induction of periph-
eral sensitization by peripheral nerve inﬂammation and oxidative
stress-induced nerve injury. Furthermore, the activation of spinal
microglia is a crucial component of diabetic neuropathic pain (54).
Therefore, it is also possible that the inhibition of activated
microglia by TRPM2 deﬁciency decreases STZ-induced diabetic
neuropathic pain.
5. Conclusion
The present results demonstrated that TRPM2 deﬁciency has
anti-allodynic effects in a wide range of inﬂammatory and neuro-
pathic pain mouse models, including acute inﬂammatory pain,
osteoarthritis pain, chronic pain in multiple sclerosis,
chemotherapy-induced peripheral neuropathy, and diabetic pain-
ful neuropathy, as well as in classical inﬂammatory pain and pe-
ripheral nerve injury-induced neuropathic pain, which are based
on peripheral and central neuroinﬂammation, rather than noci-
ceptive pain. These ﬁndings suggest that TRPM2 is a promising
drug target for these pathological pains.
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